NewMarket Corp: Two Businesses, One Multiple

Defense primes in Q4 2025 / Q1 2026 calls gave explicit production guidance: 100% growth on AIM-9X, 200% on THAAD, 300% on PAC-3 and Standard Missile (Karman, 2026-03-25). Lockheed signed a seven-year PAC-3 MSE framework with the Department of War. L3Harris guided MSL segment sales to $4.4B, raised capex 35-40% to $600M largely for solid rocket motor capacity, and committed to filing an S-1 for an Aerojet Rocketdyne IPO later in 2026. Northrop disclosed "second source initiatives" for SRMs. Every oxidizer in every US-made solid rocket motor traces back to ammonium perchlorate. One American company makes it: AMPAC, a subsidiary of NewMarket Corporation (NEU).

AMPAC is 10% of NEU's revenue, buried inside a petroleum additives cyclical that is 90% of the franchise. The consolidated multiple reflects neither business accurately. This is not a thesis about cheap cash flow — it is about a structural chokepoint trapped in the wrong corporate wrapper.

What the filing says

Q1 2026 10-Q (filed 2026-04-23). Petroleum additives: volumes -6.9% YoY (North America -10.7%, Asia Pacific -9.4%), operating margin 22.1% vs 22.0% prior year on favorable raw material costs. Specialty materials: operating profit $12.4M vs $23.2M (-46.6%) on "a shift in quarterly product shipment mix at AMPAC"; management flagged such variation as structural. Net sales $609.8M (-5.5%); OCF $124M vs $120M. Capital return: $125.6M of Q1 buybacks at $616.90 average — 2.1% of float retired in one quarter, funded by $106M revolver draw. Leverage 1.36x against 3.75x covenant. AMPAC +50% capacity expansion on track for end-2026, $14.5M of capex deployed in Q1. New disclosure: government shutdown flagged as specialty materials risk. Tariff language unchanged and unquantified.

What the market thinks

Stock closed $683, +6.46% on earnings day. Four analyst ratings on file, most recent from 2019. There is no active sell-side consensus to anchor against — reported forward multiples are mechanical artifacts. The honest read: at $683, the market prices 15.5x FY2025 actual EPS and roughly 16x a reasonable FY2026 mid — a normal cyclical trough multiple for a quality chemicals franchise. Options: ATM IV 52.6% at the 95th percentile pre-print, P/C 0.00, max pain $590. All call flow, no put demand. With 9.2M shares out and zero coverage, that positioning is either sophisticated or pure lottery — the disclosures do not let us discriminate.

Why the gap exists

Sum-of-parts math. Pet additives at 14-16x on ≈$40 FY2026 EPS contribution ≈ $530-670/share. AMPAC plus Calca at SRM-comp 15-20x on ≈$5-7/share EPS contribution ≈ $60-140/share. Total $600-830. Against $683 spot, the AMPAC leg is underpriced by roughly $50-100/share — 7-15% of the stock. Meaningful, but modest, and concentrated in 10% of revenue. This is not a 2x mispricing. The interesting claim is not that NEU is cheap today; it is that AMPAC's share of intrinsic value grows over 2026-2028 as the +50% expansion monetizes against 100-300% prime ramps, and no one currently models the segment correctly. Chemicals analysts discount 10% of revenue; defense analysts will not initiate on a chemicals name.

Cross-ticker corroboration on both legs. Five peers (CLH, DINO, KWR, FUL, NGVT) confirm the Q4 2025 → Q1 2026 base oil tailwind was industry-wide — NEU's margin hold is not operational alpha. FUL's post-Hormuz commentary already documents raw material inversion: 40+ force majeure notices, VAM spot +300% in Europe, 10-40% price increases on specialty chemical inputs. That headwind arrives for NEU in Q2 with a 1-2 quarter lag. Seven defense primes (LMT, LHX, NOC, KRMN, RTX, KTOS, DCO) corroborate the demand side with record backlogs and capacity investment.

Risks (ranked)

1. Q2 petroleum additives margin reversion. The Q1 margin hold was an industry raw material tailwind now dated. Margin likely compresses below 22% when the Q2 10-Q prints in late July; our internal estimate assigns ≈70% to this. Stock moves toward $600 on that print.
2. NOC second-source initiatives. Defense primes spending $600M-class capex on SRM capacity are also motivated to reduce single-source dependency. AMPAC's monopoly has a multi-year ceiling, not an immediate one, but it exists and belongs in the structural view.
3. Vehicle friction. Owning AMPAC via NEU means paying 7-9x cyclical exposure for every unit of structural exposure. The thesis requires 12-24 months to dominate P&L even if correct.
4. Segment opacity. AMPAC and Calca report as one line. Q1's $12.4M specialty materials OP could be any mix of AMPAC softness and Calca contribution; the thesis cannot be verified from disclosures alone.
5. Tariff exposure unquantified. Flagged in the outlook without sizing. APAC -9.4% volumes may be partially policy-driven rather than purely cyclical.

Catalysts

• Late July 2026 — Q2 2026 10-Q. Pet additives margin trajectory resolves the cyclical read.
• H2 2026 — LHX files Aerojet S-1. If it prices, a public SRM pure-play forces segment-level valuation onto NEU. This is a redirect signal more than a hold-and-add: the cleaner way to own the theme would be to rotate into the pure-play at IPO rather than continue renting the exposure via NEU.
• End-2026 — AMPAC +50% capacity expansion completes. Narrative catalyst; P&L impact lags 6-12 months on qualification.
• February 2027 — FY2026 results.

What would change our mind

• Q2 pet additives margin holds >22% → industry tailwind more durable than FUL suggests, cyclical bear framing weakens.
• LHX abandons the Aerojet S-1 plan → the most legible SRM-comp catalyst disappears; segment-level rerate mechanism weakens.
• NOC or LHX announces a material second-source AP program with a named alternative supplier → AMPAC monopoly ceiling crystallizes earlier than expected.
• Gottwald family insider sales exceed $5M in a quarter → structural signal overrides external thesis.
• NEU breaks out AMPAC P&L separately → resolves opacity, enables direct thesis verification.

What to do

No position at $683. The vehicle friction outweighs the modest near-term mispricing, and the Q2 setup skews bearish. For the theme, cleaner vehicles exist today: KRMN, MOG-A, and LHX offer direct exposure to the defense SRM ramp without the petroleum additives drag. For NEU specifically, monitor for $620-650 entry after Q2 margin compression (meaningful edge), or $580-600 on panic (strong edge). Redirect capital to the Aerojet pure-play at IPO if the S-1 files. Trailing regression confirms the structural picture: idio variance 89.5%, but α/σ_idio of 0.10 over the trailing year — statistical idiosyncrasy without economic edge at today's price.

Evidence